Small Cell Lung Cancer

Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition.

Alexander Spira, MD, PhD, FACP, and Joshua Sabari, MD, detail possible therapeutic options for KRAS-mutated NSCLC, focusing on adagrasib and treating brain metastases.

Veterans often have characteristics and comorbidities that can make them less likely to be included in clinical trials.

Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments.

Martin Dietrich, MD, PhD, explains what KRAS G12C mutations in NSCLC are and how common they are within the NSCLC landscape.

Daniel Culver, DO, details how COVID-19 has impacted the treatment of ILD.

Kristin Highland, MD, and Ryan Haumschild, PharmD, MS, MBA, compare management tools to self-regulation for the best ILD treatment outcome, as well as patient access to nintedanib, pirfenidone, and tocilizumab through special pharmacies.

Over the past decade, the Veterans Health Administration (VHA) has sought to boost lung cancer screening rates, but several challenges remain.

A university hospital saw an initial drop of new cases, but treatment efficacy was unaffected.

In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population.

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers.

Alexander Spira, MD, PhD, FACP provides an overview of molecular testing in NSCLC.

Dr Paul Noble comments on the role lung transplants play in ILD treatment.

Daniel Culver, DO, concludes the clinical trial discussion by elaborating on Dr Highland’s assessments of the data that support the use of nintedanib, pirfenidone, and tocilizumab when treating IPF, PF-ILD, and SSc-ILD.

Patients who received a diagnosis of small cell lung cancer (SCLC) between 2010 and 2016 had a nearly 2% increase in overall survival vs those who received their diagnosis between 2004 and 2010.

Three medical experts highlight unmet needs they routinely run into while treating patients with NSCLC.

Joshua Sabari, MD, provides a breakdown of advanced non-small cell lung cancer (NSCLC) and its actionable mutations.

Dr Kristin Highland continues the treatment landscape discussion, focusing on systemic sclerosis ILD (SSc-ILD) and clinical trial data that studied therapy options for IPF, PF-ILD, and SSc-ILD.

The panel provides an overview of the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressing fibrosing ILD (PF-ILD).

A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.

The study, based on a case series in Japan, found the risk of grade 2 or above chemoradiation increased when durvalumab was started within 14 days of the final thoracic radiotherapy treatment.

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.

The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.

A new model may be able to better identify which patients will respond to immunotherapy.

Daniel Culver, DO, and Paul Noble, MD, highlight the types of physicians who manage patients with different forms of ILD, from diagnosis to treatment, as well as the process of referrals.

Daniel Culver, DO, and Paul Noble, MD, talk about incidence and prevalence typically seen with patients with ILD.

Drawing on data from more than 2000 patients, the researchers of the retrospective study found that pulmonary function test results were associated with overall survival in non-small cell lung cancer (NSCLC).

Researchers assessed treatment patterns and outcomes of patients with non-small cell lung (NSCLC) cancer and leptomeningeal disease exposed to osimertinib.

Results of a cross-sectional study showed former smokers eligible for lung cancer screening should be asked about recent tobacco use and exposure, while counseling about the harms of these 2 risk factors is warranted.